Income Statement Presentation 2023

Roche Group development pipeline Phase III (8 NMES + 41 Als) Registration US & EU (1 NME + 4 Als) glofitamab Tecentriq SC Roche 3L+ DLBCL all approved indications 1L DLBCL SARS-CoV-2 hospitalised SMA pediatric <2months RG3502 RG6026 Kadcyla + T HER-2+ eBC high-risk RG3648 Xolair food allergy RG6026 glofitamab+chemo 2L+ DLBCL Gazyva lupus nephritis RG7446 tiragolumab +T tiragolumab +T 1L PD-L1+ NSCLC 1L esophageal cancer RG7159 Gazyva membranous nephropathy RG7596 Polivy¹ Gazyva RG6058 tiragolumab +T tiragolumab + T locally advanced esophageal cancer stage III unresectable 1L NSCLC Xofluza RG6152 Xofluza systemic lupus erythematosus influenza, pediatric (0-1 year) influenza direct transmission RG6413+ RG6412 RG7916 Ronapreve² Evrysdi³ tiragolumab + T 1L non-squamous NSCLC Ocrevus higher dose RG1594 crovalimab* RG6107 crovalimab PNH aHUS Ocrevus SC RG3625 TNKase RG6114 RG6171 inavolisib (mPI3K alpha inh) giredestrant (SERD) giredestrant (SERD) 1L HR+ MBC RG6168 Enspryng 1L ER+/HER2-mBC RG6168 Enspryng RMS & PPMS RMS & PPMS stroke myasthenia gravis MOG-AD 2Filed in EU RG6330 giredestrant (SERD) + Phesgo KRAS G12C RG7446 Tecentriq + platinum chemo Tecentriq Tecentriq+cabozantinib T + chemo T + capecitabine or carbo/gem T + paclitaxel T + Avastin Tecentriq T+ lurbinectedin Venclexta Venclexta + azacitidine Lunsumio + lenalidomide RG7601 RG7828 RG7853 Lunsumio + Polivy Alecensa ctDNA+ high-risk MIBC 1L maintenance SCLC r/r MM t(11:14) 1L MDS 2L+ FL 2L+ DLBCL ALK+ NSCLC adj New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases ER+ BC adj 1L ER+/HER2+ BC 2L NSCLC NSCLC periadj NMIBC, high-risk RG6168 Enspryng autoimmune encephalitis RG6356 delandistrogene moxeparvovec (SRP-9001) DMD RG7845 fenebrutinib RMS 1Approved in EU, filed in US 3Approved in US, filed in EU T=Tecentriq PDS-Port Delivery System with ranibizumab *First filed in China in Q3 2022 RG7845 fenebrutinib PPMS RG6179 anti-IL-6 UME RCC adv SCCHN adj 1L TNBC TNBC adj HCC adj Susvimo (PDS) DME RG6321 Susvimo (PDS) DR Susvimo (PDS) WAMD, 36-week RG7716 Vabysmo (faricimab) Vabysmo (faricimab) BRVO CRVO Metabolism Neuroscience Ophthalmology Other Status as of February 2, 2023 78

View entire presentation